Clinical biomarkers in drug discovery and development

被引:485
作者
Frank, R [1 ]
Hargreaves, R
机构
[1] Pharmacia, Peapack, NJ 07977 USA
[2] Merck & Co Inc, West Point, PA 19486 USA
关键词
D O I
10.1038/nrd1130
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Biomarkers enable the characterization of patient populations and quantitation of the extent to which new drugs reach intended targets, alter proposed pathophysiological mechanisms and achieve clinical outcomes. In genomics, the biomarker challenge is to identify unique molecular signatures in complex biological mixtures that can be unambiguously correlated to biological events in order to validate novel drug targets and predict drug response. Biomarkers can stratify patient populations or quantify drug benefit in primary prevention or disease-modification studies in poorly served areas such as neuroclegeneration and cancer. Clinically useful biomarkers are required to inform regulatory and therapeutic decision making regarding candidate drugs and their indications in order to help bring new medicines to the right patients faster than they are today.
引用
收藏
页码:566 / 580
页数:15
相关论文
共 169 条
  • [1] Neuroendocrine responses to laboratory panic: Cognitive intervention in the doxapram model
    Abelson, JL
    Weg, JG
    Nesse, RM
    Curtis, GC
    [J]. PSYCHONEUROENDOCRINOLOGY, 1996, 21 (04) : 375 - 390
  • [2] Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study
    Albert, MA
    Danielson, E
    Rifai, N
    Ridker, PM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01): : 64 - 70
  • [3] Alonso Ariel, 2002, J Biopharm Stat, V12, P161, DOI 10.1081/BIP-120015741
  • [4] [Anonymous], GUID IND REV EST SAF
  • [5] Whole-body positron emission tomography-CT: Optimized CT using oral and IV contrast materials
    Antoch, G
    Freudenberg, LS
    Stattaus, J
    Jentzen, W
    Mueller, SP
    Debatin, JF
    Bockisch, A
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2002, 179 (06) : 1555 - 1560
  • [6] ENVIRONMENTAL FACTORS AND CANCER INCIDENCE AND MORTALITY IN DIFFERENT COUNTRIES, WITH SPECIAL REFERENCE TO DIETARY PRACTICES
    ARMSTRONG, B
    DOLL, R
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1975, 15 (04) : 617 - 631
  • [7] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
    Atkinson, AJ
    Colburn, WA
    DeGruttola, VG
    DeMets, DL
    Downing, GJ
    Hoth, DF
    Oates, JA
    Peck, CC
    Schooley, RT
    Spilker, BA
    Woodcock, J
    Zeger, SL
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 89 - 95
  • [8] BALLINGER JR, 2001, J CLIN PHARM
  • [9] Distribution of aggrecanase (ADAMts 4/5) cleavage products in normal and osteoarthritic human articular cartilage: the influence of age, topography and zone of tissue
    Bayliss, MT
    Hutton, S
    Hayward, J
    Maciewicz, RA
    [J]. OSTEOARTHRITIS AND CARTILAGE, 2001, 9 (06) : 553 - 560
  • [10] Advances in medical statistics arising from the AIDS epidemic
    Becker, NG
    Marschner, IC
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2001, 10 (02) : 117 - 140